S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News

$132.27
+2.91 (+2.25%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$129.22
$133.13
50-Day Range
$120.42
$169.29
52-Week Range
$117.58
$212.00
Volume
1.17 million shs
Average Volume
956,417 shs
Market Capitalization
$15.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.95
30 days | 90 days | 365 days | Advanced Chart
Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Alnylam Pharmaceuticals logo

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Headlines

Alnylam Pharma Tops Q1 EPS by 35c
Alnylam Pharmaceuticals Inc. Q1 Loss Decreases, beats estimates
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
1,665
Year Founded
2002

Sales & Book Value

Annual Sales
$844.29 million
Book Value
$3.32 per share

Profitability

Net Income
$-852.82 million
Net Margins
-101.46%
Pretax Margin
-101.39%

Debt

Price-To-Earnings

Miscellaneous

Free Float
119,123,000
Market Cap
$15.98 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/28/2022
Today
5/20/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.51 out of 5 stars

Medical Sector

133rd out of 1,420 stocks

Pharmaceutical Preparations Industry

53rd out of 679 stocks

Analyst Opinion: 4.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

Is Alnylam Pharmaceuticals a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alnylam Pharmaceuticals stock.
View analyst ratings for Alnylam Pharmaceuticals
or view top-rated stocks.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Alnylam Pharmaceuticals
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, April, 28th. The biopharmaceutical company reported ($2.00) EPS for the quarter, missing analysts' consensus estimates of ($1.84) by $0.16. The biopharmaceutical company earned $186.90 million during the quarter, compared to the consensus estimate of $242.82 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 137.44% and a negative net margin of 101.46%. The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.71) earnings per share.
View Alnylam Pharmaceuticals' earnings history
.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $870.00 million-$930.00 million, compared to the consensus revenue estimate of $1.17 billion.

What price target have analysts set for ALNY?

17 brokers have issued twelve-month price objectives for Alnylam Pharmaceuticals' shares. Their forecasts range from $103.00 to $430.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $219.76 in the next twelve months. This suggests a possible upside of 66.1% from the stock's current price.
View analysts' price targets for Alnylam Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the following people:
  • Mr. Michael W. Bonney B.A., Exec. Chairman (Age 64, Pay $106.25k)
  • Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB, CEO & Director (Age 59, Pay $1.24M)
  • Dr. Akshay K. Vaishnaw M.D., Ph.D., Pres (Age 59, Pay $1.09M)
  • Mr. Jeffrey V. Poulton M.B.A., CFO & Exec. VP (Age 54, Pay $893.47k)
  • Dr. Alfred W. Boyle Ph.D., Chief Technical Operations & Quality Officer
  • Dr. Kevin Joseph Fitzgerald Ph.D., Sr. VP, Head of Research & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom, Sr. VP of Investor Relations & Corp. Communications
  • Ms. Indrani M. Lall Franchini J.D., Exec. VP, Chief Legal Officer & Sec. (Age 50)
  • Mr. Mark Baglin, VP of Global Marketing
  • Ms. Kelley Boucher, Chief Human Resource Officer
What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.96%), Baillie Gifford & Co. (8.39%), BlackRock Inc. (6.30%), Wellington Management Group LLP (5.82%), Capital World Investors (4.97%) and State Street Corp (2.41%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals
.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Baillie Gifford & Co., Polar Capital Holdings Plc, RTW Investments LP, Farallon Capital Management LLC, Loomis Sayles & Co. L P, Bellevue Group AG, and First Trust Advisors LP. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Jeffrey W Dunn, John Maraganore, Laurie Keating, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Deep Track Capital LP, The Manufacturers Life Insurance Company , Eaton Vance Management, Wellington Management Group LLP, American Century Companies Inc., Vanguard Group Inc., and Twin Tree Management LP.
View insider buying and selling activity for Alnylam Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $132.27.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals has a market capitalization of $15.98 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852.82 million in net income (profit) each year or ($7.490010) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals employs 1,665 workers across the globe.

When was Alnylam Pharmaceuticals founded?

Alnylam Pharmaceuticals was founded in 2002.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at [email protected], or via fax at 617-551-8101.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.